Roche’s Axelios Challenges Illumina | Business and Finance News

Roche’s entry into the gene sequencing game with its $750K Axelios machine sent Illumina’s stock down 1.9%, but analysts say it’s not a knockout blow—just a slow-motion challenge to the market leader still holding 70% share. Despite the dip, Illumina’s stock is up 30% year-to-date and hit a new 52-week high, as Barclays analyst Luke Sergott even raised his price target to $145, betting on broader sector momentum. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e07194381ec4b597